Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-28EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.
The EMA authorizes Mounjaro (tirzepatide) for therapeutic use in type 2 diabetes, obesity, and overweight conditions.
-
EMA approval · 2026-08-18EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.
EMA authorised Mounjaro (tirzepatide) for therapeutic use in type 2 diabetes mellitus, obesity, and overweight conditions.
-
FDA approval · 2026-08-11FDA Approved: JANUMET — Supplemental Application (Merck Sharp & Dohme LLC)
Supplemental application for JANUMET (sitagliptin and metformin HCl) submitted by Merck to FDA for a label-related or indication-related cha…
-
FDA approval · 2026-08-11FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA supplemental application approval for INVOKAMET (canagliflozin and metformin hydrochloride) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Laurus Labs Limited)
FDA supplemental application approval for Metformin Hydrochloride (generic) by Laurus Labs Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA supplemental approval for Metformin Hydrochloride from Amneal Pharmaceuticals of New York LLC.
-
FDA approval · 2026-08-11FDA Approved: FORTAMET — Supplemental Application (ANDRX LABS LLC)
Supplemental application approval for Fortamet (metformin hydrochloride) by Andrx Labs LLC.
-
FDA approval · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA supplemental approval for Metformin Hydrochloride by Amneal Pharmaceuticals LLC.
-
FDA approval · 2026-08-11FDA Approved: GLIPIZIDE AND METFORMIN HYDROCHLORIDE — Supplemental Application (NOVITIUM PHARMA)
Supplemental approval for a combination product containing glipizide and metformin hydrochloride by Novitium Pharma.
-
FDA approval · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (IPCA LABS LTD)
FDA approves a supplemental application for metformin hydrochloride from IPCA Labs Ltd.
-
FDA approval · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE ORAL SOLUTION — Supplemental Application (TRUPHARMA, LLC)
Supplemental application approval for Metformin Hydrochloride Oral Solution by Trupharm a, LLC to support a new or revised formulation and/o…
-
FDA approval · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (ACTAVIS ELIZABETH)
Supplemental application approval for Metformin Hydrochloride by Actavis Elizabeth.
-
FDA approval · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (ScieGen Pharmaceuticals, Inc.)
FDA approves a supplemental application for metformin hydrochloride extended-release tablets from ScieGen Pharmaceuticals, Inc., signaling a…
-
EMA approval · 2026-08-06EMA Authorised: Synjardy (empagliflozin;metformin) — Boehringer Ingelheim
Synjardy (empagliflozin; metformin) has been authorised by EMA for type 2 diabetes mellitus.
-
EMA approval · 2026-07-02EMA Authorised: Suliqua (insulin glargine;lixisenatide) — Sanofi Winthrop Industrie
Suliqua (insulin glargine and lixisenatide) has been authorised for type 2 diabetes mellitus in the European Union.
-
EMA approval · 2026-06-25EMA Authorised: Trajenta (linagliptin) — Boehringer Ingelheim International GmbH
Trajenta (linagliptin) has been authorised for use in the European Union for type 2 diabetes mellitus.
-
EMA approval · 2026-06-15EMA Authorised: Sitagliptin / Metformin hydrochloride Mylan (sitagliptin hydrochloride monohydrate;metformin hydrochloride) — Mylan Pharmaceuticals Limited
Authorised combination tablet of sitagliptin and metformin hydrochloride by Mylan Pharmaceuticals Limited for Type 2 diabetes mellitus.
-
EMA approval · 2026-06-11EMA Authorised: Qtern (saxagliptin;dapagliflozin propanediol monohydrate) — Astra Zeneca AB
The EMA has authorised Qtern (saxagliptin and dapagliflozin propanediol monohydrate) for treatment of type 2 diabetes and related metabolic …
-
EMA approval · 2026-06-11EMA Authorised: Edistride (dapagliflozin propanediol monohydrate) — AstraZeneca AB
Edistride, containing dapagliflozin propanediol monohydrate, has been authorised for treatment in type 2 diabetes, systolic heart failure, h…
-
EMA approval · 2026-06-11EMA Authorised: Forxiga (dapagliflozin propanediol monohydrate) — AstraZeneca AB
Forxiga (dapagliflozin propanediol monohydrate) has been authorised for use in the European Medicines Agency, with indications including Typ…
-
EMA approval · 2026-06-08EMA Authorised: Jentadueto (linagliptin;metformin) — Boehringer Ingelheim International GmbH
European Medicines Agency authorizes Jentadueto (linagliptin/metformin) for type 2 diabetes mellitus.
-
EMA approval · 2026-06-05EMA Authorised: Ebymect (dapagliflozin propanediol monohydrate;metformin hydrochloride) — AstraZeneca AB
Authorised diabetes medicine combining dapagliflozin propanediol monohydrate with metformin hydrochloride for type 2 diabetes.
-
EMA approval · 2026-06-05EMA Authorised: Xigduo (metformin hydrochloride;dapagliflozin propanediol monohydrate) — AstraZeneca AB
Xigduo (metformin hydrochloride; dapagliflozin propanediol monohydrate) has been authorised for type 2 diabetes mellitus in the European Uni…
-
EMA approval · 2026-04-22EMA Authorised: Forxiga (dapagliflozin propanediol monohydrate) — AstraZeneca AB
EMA authorised Forxiga (dapagliflozin propanediol monohydrate) for type 2 diabetes mellitus, heart failure (systolic), and chronic kidney di…
-
EMA approval · 2026-04-22EMA Authorised: Rybelsus (semaglutide) — Novo Nordisk A/S
The European Medicines Agency authorised Rybelsus (semaglutide) by Novo Nordisk A/S for the treatment of Type 2 diabetes mellitus.